Abstract: Novel ester derivatives of ascorbic acid and 2-keto-acid saccharides are provided wherein the ester is introduced by ester bond formation between at least one hydroxy-functionality on the ascorbic acid or 2-keto-acid saccharide and a carboxy-functional organosiloxane, or between a 2-keto-gulonic acid and a hydroxy-functional organosiloxane, as well as methods for their synthesis. Treatment, cosmetic, and personal care formulations comprising the novel esters are also provided, including controlled release forms thereof.

Abstract: A method of obtaining a solid component rich in a petroselinic compound from the seed of a plant of the Apiaceae or Araliaceae families, the method comprising: (a) treating a portion of the seed of the plant with an extraction solvent; and (b) inducing formation of the solid component.

Abstract: A composition, systems for dispensing the composition and methods for the use of the composition are described. The composition comprises: (A) Monohydric alcohol in an amount sufficient to provide antimicrobial activity; (B) Surfactant comprising a dimethicone surfactant; and (C) Builder, the builder in an amount sufficient to provide stability or to improve the stability of a foam formed from the composition.

Abstract: The invention describes the unexpected solubility characteristics of a number of cosmetic esters when used as solvents during the crosslinking reaction of silicone polymers to make elastomers, their use as diluting media and the uses of these ester elastomer mixtures in cosmetic and personal care products.

Abstract: The invention relates to methods and compositions for treating and preventing pulmonary hemorrhage in an animal, and for reducing red blood cells in the airways of an animal. More particularly, the invention relates to methods and compositions for treating and preventing pulmonary hemorrhage in an animal, and for reducing red blood cells in the airways of an animal wherein a feed composition comprising an about 3:1 to an about 1:3 ratio of docosahexaneoic acid to eicosapentaenoic acid is fed to the animal.

Abstract: This document provides methods and materials related to modulating body weight. For example, methods and materials related to treating obesity, reducing body weight, preventing body weight gain, increasing body weight, and identifying agents having the ability to treat obesity and reduce body weight are provided.

Abstract: The invention relates to compositions comprising pholyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers with units having formula (I), said units being characterised by the simultaneous presence of a resorcinol nucleus (nucleus A) and a para-phenol nucleus (nucleus B) which are interconnected by a carbon bond C, said derivatives being over-activated, in respect of the nucleophilic power thereof, by alkylation of at least one phenol function of each constituent monomer unit and stabilised by sterification by mixtures of fatty acids in proportions reflecting those of vegetable oils formed mainly by unsaturated fatty acids of all of the other phenol functions. The invention is suitable for use in cosmetics, dietetics and therapeutics.

Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.

Abstract: The invention relates to the use of esters of 2-butyloctanol with C2-36 carboxylic acids or C2-36 dicarboxylic acids in cosmetic and/or pharmaceutical preparations. The compounds are characterised by a particularly light feeling.

Abstract: The invention relates to the use of esters of 2-ethylbutanol with C4-36 carboxylic acids or C4-36 dicarboxylic acids in cosmetics and/or pharmaceutical preparations. The compounds are characterised by a particularly light feeling.

Abstract: Use of medium-chain length fatty acids such as capric acid, caprylic acid or lauric acid and their salts or mono- or di- or triglycerides as nephroprotection agents to protect against renal failure progression in chronic kidney diseases This includes the treatment of kidney diseases associated with nephrectomy, renal fibrosis, glomerular scelrosis and end-stage renal disease Also includes the protection of the kidney against cytotoxic agent used in chemotherapy or autoimmune diseases or transplantation Further includes the treatment of renal failure progression associated with hypertension, infarct, tumour, diabetes mellitus, autoimmunity or inflammation.

Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.

Abstract: The subject application provides an aqueous composition suitable for use as an artificial tear solution comprising one or more lipids produced by an enzyme of the diacylglycerol acyltransferase 2 (DGAT2) family and/or the acyl-CoA cholesterol acytransferase (ACAT) family. This invention also provides related methods.

Abstract: A composition for external application to skin, containing a compound represented by formula (I) or a salt thereof, and/or a quaternary ammonium salt represented by formula (II): wherein R1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO— or —O—; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R3 is an alkyl group having 1 to 4 carbon atoms; R2 and R3 are the same as or different from each other; R4, R5 and R6, which may the same as or different from each other, each are an alkyl group having 1 to 4 carbon atoms; and A? is a counter ion.

Abstract: A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided. An oral administration composition having a body fat reducing action and/or a neutral fat reducing action, which is a composition comprising a carotenoid and a sphingolipid or a carotenoid and a flavonoid and/or a derivative thereof, preferably a composition comprising a cryptoxanthin and a sphingolipid or a cryptoxanthin and a flavonoid and/or a derivative thereof, wherein the cryptoxanthin and/or the sphingolipid and/or the flavonoid are derived from a citrus fruit and the citrus fruit is preferably Citrus unshiu.

Abstract: The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics.

Abstract: A method for the control of insects breeding on water surfaces and particularly mosquitoes, comprising blending in a high shear mixer water, the ester of a fatty acid of 10 to 25 carbon atoms and a low molecular weight alcohol, such as methanol or ethanol, an emulsifying agent and a thickener until an emulsion containing the ester with droplet sizes ranging from 1 to 20 microns in diameter is obtained and applying such to the surface of insect infested water in sufficiently diluted form, to break the emulsion and form a thin continuous film.

Abstract: Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.

Abstract: Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa.

Abstract: The invention relates to esters of 2-propylheptanoic acid and also to the use of esters of 2-propylheptanoic acid in cosmetic and/or pharmaceutical preparations. The compounds are characterized by the particularly lightweight sensation thereof.

Abstract: The present invention relates the manufacture of conjugated linoleic acid, and in particular, to feeds and food products containing conjugated linoleic acid. Accordingly, processes for producing conjugated linoleic acid of high purity are disclosed. These processes utilize alcoholate catalysts and esters of sunflower oil, safflower oil, or corn oil as the source of linoleic acid. The esters of conjugated linoleic acid produced by the process can be used in animal feeds and in food products suitable for human consumption. Furthermore, the esters can be converted into free fatty acids or incorporated into triglycerides.

Abstract: The present invention relates to a composition comprising: (a) at least one alkoxylated polyamine; (b) at least one organic acid chosen from alkyl acids, alkoxylated monoacids, and mixtures thereof; (c) at least one lipophilic compound; and (d) at least one solvent comprising water. Such a composition is clear in appearance, and stable. The present invention also relates to a method of making such a clear composition, and to a method of cosmetic treatment of a keratinous substrate using such a composition.

Abstract: The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various vitamins.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: The invention relates to substrates impregnated with the skin-treating components which when introduced into a tumbling-type dryer in which it contacts fabric articles, the skin-treating component is transferred to the fabric articles which, when contacted with the skin of a user applies the skin-treating component to human skin.

Abstract: A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed.

Abstract: Compositions containing 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes include providing an ester of 1,3-propanediol and mixing the 1,3-propanediol ester with the source. This serves to extract the extract from the source into the ester. The processes also include separating the source from the ester and extract. Also provided are compositions containing an ester of 1,3-propanediol and an extraction product. In these compositions, the ester can have at least 3% biobased carbon.

Abstract: Gel compositions are disclosed containing a silicone polyether elastomer from the reaction of an organohydrogensiloxane having at least two SiH containing cyclosiloxane rings in its molecule, a compound or mixture of compounds having at least two aliphatic unsaturated groups in its molecule, and a hydrosilylation catalyst. The silicone polyether elastomer reaction product may itself be a gelled composition, or optionally may be contained in a carrier fluid to form a gel. The gel compositions may further contain a personal or healthcare active.

Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include icosapentanoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs.

Abstract: Capsinoids of formula (3) may be conveniently prepared in a high yield, in a short time, without using a dehydrating agent by esterification of a fatty acid of formula (1) with a hydroxymethylphenol of formula (2) using an enzyme without a solvent or in a low-polar solvent. Addition of a fatty acid represented by formula (4) is effective for stabilizing the ester compound of formula (3). wherein each symbol is as defined in the specification.

Abstract: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

Abstract: The application of active ingredients, exemplified by GML, to absorbent fibers, such as rayon fibers, used in tampon manufacture at very low levels has been found to maintain efficacy in the inhibition of the production of toxic shock syndrome toxin one (TSST-1) produced by S. aureus without overtly killing the microorganism to achieve the desired reduction while avoiding undesired test results that suggest the presence of “impurities” in some jurisdictions.

Abstract: This invention relates to a stabilized honey bee pheromone and methods of stabilizing the honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized pheromone can be used to manipulate the behavior and improve the performance of worker honey bees, resulting in overall increased vigor of the hive. The pheromone composition comprises two or more of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl linolenate, methyl oleate, methyl palmitate and methyl stearate and an antioxidant.

Abstract: Personal care compositions are provided that include an aqueous base composition and a volatile post foaming agent mixed with the base composition. The base composition comprises a lipophilic skin conditioning agent, a structuring agent, and a water soluble or water dispersible surface active agent.

Abstract: The present invention relates to the use of one or more esters of 2-hexyldeconal having fatty acids of the general formula (I) R1-COOH, wherein R1 is a linear or branched, saturated or unsaturated alkyl radical having 1 to 6 carbon atoms, in and/or for the production of cosmetic and/or pharmaceutical preparations.

Abstract: Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol, elemol, alpha-eudesmol, and ester derivatives thereof.

Abstract: Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following enzymatic or chemical hydrolysis. In various embodiments, these esterified capsaicinoids have a higher lipophilicity, lipid solubility and result in less irritation to the stomach than the parent capsaicinoid, and hence may be included in certain dietary supplement formulations, including capsules, pills and tablets dietary supplement formulations. The dietary supplement compositions may be used for pain management in mammals in vivo and/or in the treatment of various pathological conditions in humans.

Abstract: Disclosed is a novel method for preserving cosmetic/personal care formulations through a two component preservative system, said system comprising (a) Component I which functions to eliminate the existing microbial contamination load in a natural cosmetic formulation base through an optimized pasteurization method that avoids deep freezing; and (b) Component II that includes the step of adding synergistic blends of fractionated essential oils, extracts and isolated compounds to the pre-pasteurized cosmetic base obtained through the method of component I, wherein the synergistic blends sustain the effects of pasteurization through anti-microbial and anti-oxidant effects, said anti-oxidant effects enhancing further the anti-microbial effects by virtue of inhibiting lipid per oxidation that facilitates the undue proliferation of microbe.

Abstract: A composition for use as a medicament, functional food or nutritional product is described which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition. A preferred embodiment comprises a n-6/n-3 fatty acid ratio of about 2/1 to 7/1. In addition, a method of preparing the composition; use of the composition in the manufacture of a medicament, functional food or nutritional product; and a method of treatment or treatment or prevention of sepsis or inflammatory shock which comprises administering an effective amount of the composition are described.

Abstract: The present invention is directed to gelatinous elastomer compositions that are useful for topical application of biologically active agents. In certain embodiments, the invention is directed to a gelatinous elastomer composition comprising about 1.0% to 50.0% block copolymer, about 0% to 98% mineral and/or synthetic oil, and about 0.0% to 98% triglyceride oil, about 0-15.0% free fatty acids, about 0-30% of a tack modification agent, about 0-20.0% of a biologically active agent and, optionally a phytosterol, ceramide and/or bisabolol. The gelatinous elastomer compositions are useful for applying a biologically active agent to a mammal. In certain embodiments, the gelatinous elastomer composition is formed into a molded article.

Abstract: The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel.

Abstract: The present invention is related to a pharmaceutical combination of a glucocorticoid and a ?-cyclodextrin conjugated vitamin A derivative complex as well as a pharmaceutical composition comprising the same. The combination and the composition of the invention can be used for reducing or eliminating skin atrophy induced by treatment with glucocorticoids (GC). Also comprised is a method for reducing or eliminating skin atrophy induced by GC treatment. Furthermore the invention concerns a kit comprising a glucocorticoid and a ?-cyclodextrin conjugated vitamin A derivative complex.

Abstract: Provided are compositions comprising a polymeric emulsifier, a hydrophobic agent, a wetting agent having at least one sulfonate group and at least one base-neutralizable carboxylic acid group, and a hydrophilic particulate material. Also provided are methods of mitigating diaper dermatitis using the composition, and methods of promoting the benefits associated with the compositions.

Abstract: The present invention relates to polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester, processes therein, pharmaceutical compositions thereof, and uses therewith.

Abstract: The administration of nutritional supplements such as phosphatidylcholine; linoleic acid and alpha linolenic acid in an approximately 4:1 (v/v) ratio; and mineral supplements provides an effective method for the treatment of ALS. Subjects presenting with symptoms indicative of ALS can therefore be treated with these nutritional supplements to inhibit progression of ALS. Subjects at risk for developing ALS can also be treated with these nutritional supplements to delay the onset of ALS symptoms.

Abstract: Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15% by weight fatty acid moieties with carbon chain lengths of C18 or higher. Additives may be disposed in or on the hard cosmetic particles and delivered when the cosmetic particles are broken proximate a target such as the skin, hair or nails of a mammalian subject or another target. The transformable hard cosmetic particles permit the storage and shipment of intact cosmetic particles yet transform in situ to achieve the benefits of soft cosmetic particles.

Abstract: This invention relates to certain sugar esters of phytosterols of formula (I).

Abstract: The present invention relates to pheromone mixture comprising 2,9 diacetoxyundecane, 2,10-diacetoxyundecane and 2-acetoxyundecane, as a racemate or, biologically active stereoisomers thereof, as well as a method for monitoring and/or mating disruption of swede midge, Contarinia nasturtii, in Brassica vegetables, in particular Brussels sprouts, cauliflower and broccoli.

Abstract: The invention features pharmaceutical formulations containing octanol and esters thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors.

Abstract: Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.